Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inex Marqibo Phase III Preparation Includes Company Restructuring

This article was originally published in The Pink Sheet Daily

Executive Summary

The company will reduce its workforce from 165 to 62 employees, including executive-level resignations. Inex plans a Phase III comparative trial of the liposomal vincristine product in first- or second-line non-Hodgkin’s lymphoma or acute lymphoblastic leukemia following a negative advisory committee review for third-line NHL.

You may also be interested in...



Inex Restructures: COO Is Timothy Ruane, Senior Execs Depart

Inex is shedding 60% of its workforce in a cost-cutting move aimed at reducing cash burn to under $1 mil. a month. CEO David Main and senior execs depart under reorganization, the second since an advisory committee’s unfavorable recommendation for Inex’ oncologic Marqibo.

Inex Restructures: COO Is Timothy Ruane, Senior Execs Depart

Inex is shedding 60% of its workforce in a cost-cutting move aimed at reducing cash burn to under $1 mil. a month. CEO David Main and senior execs depart under reorganization, the second since an advisory committee’s unfavorable recommendation for Inex’ oncologic Marqibo.

Inex/Enzon's Marqibo Accelerated Approval Application "Not Approvable"

FDA recommends additional randomized studies comparing Marqibo to other chemotherapy agents; the agency also cites CMC deficiencies. The "not approvable" letter follows a negative committee review for the non-Hodgkin's lymphoma therapy.

Topics

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel